The impact of chronic liraglutide therapy on glucagon secretion in type 2 diabetes: Insight from the LIBRA trial

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 10, 2015, Pages 3702-3709

  Kramer, Caroline K ^a,c   Zinman, Bernard ^a,b,c   Choi, Haysook ^a   Connelly, Philip W ^c,d   Retnakaran, Ravi ^a,b,c  

^a MOUNT SINAI HOSPITAL   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCAGON; GLUCOSE; INSULIN; LIRAGLUTIDE; METFORMIN; PLACEBO; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; FEMALE; GLUCAGON RELEASE; HUMAN; HYPERGLUCAGONEMIA; INSULIN RELEASE; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN SECRETION; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; AGED; BLOOD; DIABETES MELLITUS, TYPE 2; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME;

AGED; BLOOD GLUCOSE; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GLUCAGON; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIRAGLUTIDE; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84943799774     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-2725     Document Type: Article

References (37)

1. D'Alessio D. The role of dysregulated glucagon secretion in type 2 diabetes. Diabetes Obes Metab. 2011;13(suppl 1):126-132.
2. Unger RH, Orci L. Paracrinology of islets and the paracrinopathy of diabetes. Proc Natl Acad Sci USA. 2010;107:16009-16012.
3. Lund A, Bagger JI, Christensen M, Knop FK, Vilsboll T. Glucagon and type 2 diabetes: The return of the alpha cell. Curr Diab Rep. 2014;14:555.
4. Dinneen S, Alzaid A, Turk D, Rizza R. Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM. Diabetologia. 1995;38:337-343.
5. Shah P, Vella A, Basu A, Basu R, Schwenk WF, Rizza RA. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2000;85:4053-4059.
6. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagonlike peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36:741-744.
7. Hare KJ, Knop FK, Asmar M, Madsbad S, Deacon CF, Holst JJ, Vilsbøll T. Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2009; 94:4679-4687.
8. Degn KB, Juhl CB, Sturis J, et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and-and-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes. 2004;53:1187-1194.
9. Hermansen K, Bækdal TA, Düring M, et al. Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: A randomized, doubleblind, placebo-controlled, cross-over trial. Diabetes Obes Metab. 2013;15:1040-1048.
10. Retnakaran R, Kramer CK, Choi H, Swaminathan B, Zinman B. Liraglutide and the preservation of pancreatic-cell function in early type 2 diabetes: The LIBRA trial. Diabetes Care. 2014;37:3270-3278.
11. Kramer CK, Choi H, Zinman B, Retnakaran R. Glycemic variability in patients with early type 2 diabetes: The impact of improvement in-cell function. Diabetes Care. 2014;37:1116-1123.
12. Kramer CK, Zinman B, Choi H, Retnakaran R. Effect of short-term intensive insulin therapy on post-challenge hyperglucagonemia in early type 2 diabetes [published online ahead of print June 16, 2015]. J Clin Endocrinol Metab.
13. Kramer CK, Choi H, Zinman B, Retnakaran R. Determinants of reversibility of-cell dysfunction in response to short-term intensive insulin therapy in patients with early type 2 diabetes. Am J Physiol Endocrinol Metab. 2013;305:E1398-E1407.
14. Retnakaran R, Qi Y, Opsteen C, Vivero E, Zinman B. Initial shortterm intensive insulin therapy as a strategy for evaluating the preservation of-cell function with oral antidiabetic medications: A pilot study with sitagliptin. Diabetes Obes Metab. 2010;12:909-915.
15. Retnakaran R, Yakubovich N, Qi Y, Opsteen C, Zinman B. The response to short-term intensive insulin therapy in type 2 diabetes. Diabetes Obes Metab. 2010;12:65-71.
16. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22:1462-1470.
17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
18. Retnakaran R, Shen S, Hanley AJ, Vuksan V, Hamilton JK, Zinman B. Hyperbolic relationship between insulin secretion and sensitivity on oral glucose tolerance test. Obesity. 2008;16:1901-1907.
19. Retnakaran R, Qi Y, Goran MI, Hamilton JK. Evaluation of proposed oral disposition index measures in relation to the actual disposition index. Diabet Med. 2009;26:1198-1203.
20. DeFronzo RA, Tripathy D, Schwenke DC, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011;364:1104-1115.
21. Ahrén B, Larsson H. Impaired glucose tolerance (IGT) is associated with reduced insulin-induced suppression of glucagon concentrations. Diabetologia. 2001;44:1998-2003.
22. Baron AD, Schaeffer L, Shragg P, Kolterman OG. Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes. 1987;36:274-283.
23. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: A physiological incretin in man. Lancet. 1987;2: 1300-1304.
24. Vilsbøll T, Krarup T, Madsbad S, Holst JJ. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept. 2003;114:115-121.
25. Edwards CM, Todd JF, Mahmoudi M, et al. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes. 1999; 48:86-93.
26. Drucker DJ, Buse JB, Taylor, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: A randomised, openlabel, non-inferiority study. Lancet. 2008;372:1240-1250.
27. Ahrén B, Leguizamo Dimas A, Miossec P, Saubadu S, Aronson R. Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). Diabetes Care. 2013;36:2543-2550.
28. Rosenstock J, Hanefeld M, Shamanna P, et al. Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S). J Diabetes Complications. 2014;28:386-392.
29. Gudipaty L, Rosenfeld NK, Fuller CS, Gallop R, Schutta MH, Rickels MR. Effect of exenatide, sitagliptin, or glimepiride on-cell secretory capacity in early type 2 diabetes. Diabetes Care. 2014;37: 2451-2458.
30. Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014;124:509-514.
31. Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124:499-508.
32. Salehi M, Prigeon RL, D'Alessio DA. Gastric bypass surgery enhances glucagon-like peptide 1-stimulated postprandial insulin secretion in humans. Diabetes. 2011;60:2308-2314.
33. Gu W, Yan H, Winters KA, et al. Long-term inhibition of the glucagon receptor with a monoclonal antibody in mice causes sustained improvement in glycemic control, with reversible alpha-cell hyperplasia and hyperglucagonemia. J Pharmacol Exp Ther. 2009;331:871-881.
34. Gelling RW, Du XQ, Dichmann DS, et al. Lower blood glucose, hyperglucagonemia, and pancreatic cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci U S A. 2003;100:1438-1443.
35. Zhou C, Dhall D, Nissen NN, Chen CR, Yu R. Homozygous P86S mutation of the human glucagon receptor is associated with hyperglucagonemia, cell hyperplasia, and islet cell tumor. Pancreas. 2009;38:941-946.
36. Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes. 2001;50:609-613.
37. Meier JJ, NauckMA.Is secretion of glucagon-like peptide-1 reduced in type 2 diabetes mellitus? Nat Clin Pract Endocrinol Metab. 2008; 4:606-607.